Novo Nordisk A/S (NYSE:NVO) Given Average Recommendation of “Hold” by Brokerages

Novo Nordisk A/S (NYSE:NVO) has received an average recommendation of “Hold” from the twenty-two research firms that are currently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $53.3333.

A number of research analysts recently commented on the stock. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Tuesday. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday. Finally, Rothschild Redb raised Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th.

Novo Nordisk A/S Trading Up 7.4%

Shares of Novo Nordisk A/S stock opened at $51.66 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. The business has a fifty day simple moving average of $49.55 and a two-hundred day simple moving average of $57.16. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $93.80. The company has a market capitalization of $230.65 billion, a price-to-earnings ratio of 15.02 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.77 by $0.25. The firm had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. Research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approval of oral Wegovy — market catalyst: The FDA cleared the first oral GLP‑1 pill for weight management, giving Novo a first‑mover commercial advantage and a path to regain share lost to Eli Lilly. Read More.
• Positive Sentiment: Launch plan and pricing expected to drive near‑term sales: Novo plans a U.S. launch in early January with an introductory cash price (~$149/month for starting dose), targeting the large self‑pay market. This gives investors a near-term revenue catalyst. Read More.
• Positive Sentiment: Unusual options activity and strong volume — investor conviction: Large call buying and much higher-than-normal trading volume indicate speculative and directional interest tied to the approval. Read More.
• Positive Sentiment: Analyst commentary supportive: Some analysts (e.g., HSBC cited in recent coverage) see Novo as having an edge over Eli Lilly after getting to market first with an oral option. Read More.
• Neutral Sentiment: ETF and sector flows may amplify moves: Approval has renewed interest in health‑care/GLP‑1 ETFs, which could lift peers and the sector irrespective of Novo’s fundamentals. Read More.
• Neutral Sentiment: Demand and reimbursement are untested for a cash‑market pill: Novo will initially push the pill into self‑pay channels, so uptake and conversion to covered prescriptions remain uncertain and could temper sales growth. Read More.
• Negative Sentiment: Competitive risk from Eli Lilly and others: Analysts warn Lilly’s oral development and its strong injectable momentum remain a material competitive threat; timing of Lilly’s response could cap upside. Read More.
• Negative Sentiment: Regulatory/generic noise in other markets: Separate regulatory delays for generics and local reimbursement issues (e.g., Canada) highlight ongoing access and pricing risks outside the U.S. Read More.

Institutional Trading of Novo Nordisk A/S

Several hedge funds and other institutional investors have recently bought and sold shares of the business. True Wealth Design LLC boosted its holdings in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares during the period. Guerra Advisors Inc acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $25,000. Strengthening Families & Communities LLC bought a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $30,000. NewSquare Capital LLC grew its position in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after buying an additional 282 shares in the last quarter. Finally, Allianz SE increased its stake in Novo Nordisk A/S by 70.0% during the 3rd quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after acquiring an additional 238 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.